Summary for E2F7 (NES ID: 297)

Full Name
Transcription factor E2F7     UniProt    
Alternative Names
None
Organism
Homo sapiens (Human)    
Experimental Evidence for CRM1-mediated Export
KPT Sensitive Ref.1Targeting the XPO1-dependent nuclear export of E2F7 reverses anthracycline resistance in head and neck squamous cell carcinomas, SaenzPonce et al., Sci Transl Med, 2018
Mutations That Affect Nuclear Export
Unknown
Mutations That Affect CRM1 Binding
Unknown
Functional Export Signals
*shown as underlined residues in the full sequence
Secondary Structure of Export Signal
Unknown
Other Residues Important for Export
Unknown
Sequence
Show FASTA Format Show Domain Info by CDD Show Secondary Structure by PSIPRED Show Conservation Score by AL2CO 
        10         20         30         40         50         60 
MEVNCLTLKD LISPRQPRLD FAVEDGENAQ KENIFVDRSR MAPKTPIKNE PIDLSKQKKF 

        70         80         90        100        110        120 
TPERNPITPV KFVDRQQAEP WTPTANLKML ISAASPDIRD REKKKGLFRP IENKDDAFTD 

       130        140        150        160        170        180 
SLQLDVVGDS AVDEFEKQRP SRKQKSLGLL CQKFLARYPS YPLSTEKTTI SLDEVAVSLG 

       190        200        210        220        230        240 
VERRRIYDIV NVLESLHLVS RVAKNQYGWH GRHSLPKTLR NLQRLGEEQK YEEQMAYLQQ 

       250        260        270        280        290        300 
KELDLIDYKF GERKKDGDPD SQEQQLLDFS EPDCPSSSAN SRKDKSLRIM SQKFVMLFLV 

       310        320        330        340        350        360 
SKTKIVTLDV AAKILIEESQ DAPDHSKFKT KVRRLYDIAN VLTSLALIKK VHVTEERGRK 

       370        380        390        400        410        420 
PAFKWIGPVD FSSSDEELVD VSASVLPELK RETYGQIQVC AKQKLARHGS FNTVQASERI 

       430        440        450        460        470        480 
QRKVNSEPSS PYREEQGSGG YSLEIGSLAA VYRQKIEDNS QGKAFASKRV VPPSSSLDPV 

       490        500        510        520        530        540 
APFPVLSVDP EYCVNPLAHP VFSVAQTDLQ AFSMQNGLNG QVDVSLASAA SAVESLKPAL 

       550        560        570        580        590        600 
LAGQPLVYVP SASLFMLYGS LQEGPASGSG SERDDRSSEA PATVELSSAP SAQKRLCEER 

       610        620        630        640        650        660 
KPQEEDEPAT KRQSREYEDG PLSLVMPKKP SDSTDLASPK TMGNRASIPL KDIHVNGQLP 

       670        680        690        700        710        720 
AAEEISGKAT ANSLVSSEWG NPSRNTDVEK PSKENESTKE PSLLQYLCVQ SPAGLNGFNV 

       730        740        750        760        770        780 
LLSGSQTPPT VGPSSGQLPS FSVPCMVLPS PPLGPFPVLY SPAMPGPVSS TLGALPNTGP 

       790        800        810        820        830        840 
VNFSLPGLGS IAQLLVGPTA VVNPKSSTLP SADPQLQSQP SLNLSPVMSR SHSVVQQPES 

       850        860        870        880        890        900 
PVYVGHPVSV VKLHQSPVPV TPKSIQRTHR ETFFKTPGSL GDPVLKRRER NQSRNTSSAQ 

       910                                                        
RRLEIPSGGA D
3D Structures in PDB
Not Available
Comments
E2F7 is a member of the E2F family of transcriptional inhibitors. Saenz-Ponce et al found that E2F7 is specifically mislocalized to the cytoplasm in squamous cell carcinomas cells, and the mislocalization correlates with doxorubicin resistance. Selinexor (a KPT-SINE inhibitor) and CRM1 knockdown caused nuclear accumulation of E2F7. Putative NES can be found in 1-25, no further validation of the NES have been performed so far.
References
[1]. "Targeting the XPO1-dependent nuclear export of E2F7 reverses anthracycline resistance in head and neck squamous cell carcinomas"
Saenz-Ponce N, Pillay R, de Long LM, Kashyap T, Argueta C, Landesman Y, Hazar-Rethinam M, Boros S, Panizza B, Jacquemyn M, Daelemans D, Gannon OM, Saunders NA. (2018) Sci Transl Med, 10(447):eaar7223 PubMed
User Input
Accurate identification of NESs is difficult because many sequences in the genome match the NES consensus. Therefore, some published NESs may be mistakenly identified. Please help us improve the accuracy of NESdb by providing either a positive or negative flag for the NES in this entry. Supporting comments are required to process the flag.

Supporting comments *

Flag this NES *

Positive
Negative

E-mail: